01—Abstract
Summary
Summary of the 8-K filed February 7, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2023 results in a press release dated February 6, 2024 (Exhibit 99.1), with slides for its February 7, 2024 earnings call furnished as Exhibit 99.2.
For Q4 2023, sales were $788.9 milliona, down 3% overall and down 6% organically, while reported diluted EPS was $1.43 (down 16%) and adjusted diluted EPS was $1.83 (down 9%). Operating cash flow of $201.0 million and free cash flow of $179.4 million were both up year over year. For full year 2023, the company reported record net sales of $3,273.9 million (up 3%, but down 1% organically), record reported diluted EPS of $7.85, record adjusted diluted EPS of $8.22 (up 1%), and record free cash flow of $626.8 million (up 28%). management said most end markets are stable and that the company is in the early stages of focused organic growth.
However, the timing of recovery in its Life Sciences and Analytical Instrumentation businesses remains uncertain, which moderates the full-year growth outlook. Orders fell 6% in Q4 and 7% for the full year, with organic orders down 10% and 11% respectively. During the quarter the company completed the $202.0 millionb cash acquisition of STC Material Solutions and the sale of Novotema for $8.3 million, which produced a $9.1 million loss.
For 2024, IDEX guided to full-year organic sales growth of 0% to 2%, reported diluted EPS of $7.15 to $7.45c, and adjusted diluted EPS of $8.15 to $8.45. First-quarter 2024 organic sales are projected to decline 6% to 7%, with adjusted diluted EPS of $1.70 to $1.75. Guidance excludes future acquisitions and restructuring expenses.
02—Key points
Key Highlights
- Q4 2023 sales of $788.9 million, down 3% overall and down 6% organically; full year sales were a record $3,273.9 million, up 3%.
- Q4 2023 reported diluted EPS was $1.43, down 16%; adjusted diluted EPS was $1.83, down 9%.
- Full year 2023 record free cash flow of $626.8 million, up 28%, and record operating cash flow of $716.7 million.
- Full year 2023 orders of $3,057.6 million declined 7%, with organic orders down 11%.
- 2024 guidance: full-year organic sales growth of 0% to 2% and adjusted diluted EPS of $8.15 to $8.45; Q1 2024 organic sales projected to decline 6% to 7%.
- Acquired STC Material Solutions on December 14, 2023 for $202.0 million in cash; sold Novotema on December 29, 2023 for $8.3 million, recording a $9.1 million loss.
- Health & Science Technologies segment Q4 sales fell 11% (19% organic decline), and its Adjusted EBITDA margin dropped 450 basis points to 25.8%.
03—Questions
Frequently Asked Questions
How did IDEX perform in the fourth quarter of 2023?
Sales were $788.9 million, down 3% overall and down 6% organically. Reported diluted EPS was $1.43, down 16%, and adjusted diluted EPS was $1.83, down 9%. Operating cash flow rose to $201.0 million and free cash flow to $179.4 million, up 22%.
What drove the full-year 2023 results?
Full-year sales reached a record $3,273.9 million, up 3% overall but down 1% organically, with acquisitions contributing 5%. Record reported diluted EPS of $7.85 and adjusted diluted EPS of $8.22 were driven by higher gains on business sales and lower fair value inventory step-up charges, partly offset by lower operating results, higher interest expense and amortization from new acquisitions.
What is IDEX's 2024 outlook?
The company projects full-year 2024 organic sales growth of 0% to 2%, GAAP diluted EPS of $7.15 to $7.45, and adjusted diluted EPS of $8.15 to $8.45. For the first quarter, organic sales are projected to decline 6% to 7%, with adjusted diluted EPS of $1.70 to $1.75. Management noted that timing of recovery in Life Sciences and Analytical Instrumentation remains uncertain, which moderates the full-year growth outlook.
What acquisitions and divestitures did IDEX complete in late 2023?
IDEX completed the acquisition of STC Material Solutions on December 14, 2023 for $202.0 million in cash, funded from cash on hand. It also sold Novotema for $8.3 million, net of cash remitted, on December 29, 2023, recording a $9.1 million loss. Management said its acquisition funnel is strong and its balance sheet has ample capacity.
What do the orders trends indicate?
Fourth quarter orders of $753.9 million fell 6% compared with the prior year, with organic orders down 10%. Full-year orders of $3,057.6 million declined 7%, with organic orders down 11%, partly offset by a 5% contribution from acquisitions and divestitures.
04—Continue